Immunovant, Inc. is a clinical-stage immunology company developing therapies for autoimmune diseases by inhibiting FcRn to reduce pathogenic IgG antibodies.

# Immunovant, Inc. Company Summary

## Overview
- Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.
- Its core technology involves inhibiting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies.
- The company's lead product candidate is IMVT-1402, a potentially best-in-class FcRn inhibitor designed for various IgG-mediated autoimmune diseases.
- Previously developed a first-generation anti-FcRn antibody, batoclimab (formerly IMVT-1401), which has shown promising clinical results.
- Collaborates with HanAll Biopharma, which holds key patents and rights related to its antibody technologies.

## Regulatory and Development Status
- No products are currently approved for commercial sale.
- Multiple clinical trials are ongoing for IMVT-1402 across indications including Graves’ Disease (GD), Myasthenia Gravis (MG), CIDP, Sjögren’s Disease, D2T Rheumatoid Arthritis, and Cutaneous Lupus Erythematosus.
- Company has initiated several Phase 2 and Phase 3 clinical trials, with topline results expected around 2025-2027.
- Has obtained IND approvals for six trials in the last fiscal year.
- Plans to develop and commercialize products in the U.S. and internationally, with plans for future regulatory submissions.

## Business Focus & Strategy
- Prioritizes unmet medical needs in autoimmune diseases driven by high IgG levels.
- Focuses on indications like GD, MG, CIDP, SjD, RA, CLE, and TED.
- Aims to achieve first-in-class or best-in-class efficacy with convenient self-administration formulations.
- Leverages data from previous clinical trials (batoclimab) to accelerate development of IMVT-1402.
- Will consider strategic collaborations and expansion into new indications.

## Intellectual Property
- Holds patents in the U.S., Europe, and other jurisdictions, with patent protection expiring around 2035-2046.
- Owns trademarks including "Immunovant."
- Licensed patents from HanAll with patent family coverage extending into the 2030s-2040s.

## Financial Information
- As of May 23, 2025:
  - Outstanding shares: approximately 170.9 million.
  - Market value (as of September 30, 2024): ~$1,866.6 million based on stock price of $28.51.
- Revenue and income figures are not specified; the company has a limited operating history and has never generated product revenue.
- Does not currently have manufacturing facilities and relies on third-party contract manufacturers.

## Employees
- As of March 31, 2025:
  - Total employees: 362 full-time.
  - Around 58% have advanced degrees (Ph.D., M.D., M.B.A.).
  - About 83% of employees are engaged in research and development activities.
  - Workforce composition includes over half women; no employees are unionized.

## Business Model & Commercialization
- Currently does not have sales or distribution capabilities.
- Plans to develop a small sales team targeting specialists for autoimmune indication markets.
- Potential to commercialize authorized products via partnerships or internal sales.

## Collaborations & Agreements
- HanAll Biopharma license agreement provides rights for development, manufacturing, and commercialization in multiple territories.
- Manufacturing agreements with Samsung Biologics for batoclimab supply.
- Corporate structure as a majority-owned subsidiary of Roivant Sciences Ltd.

## Summary
Immunovant develops FcRn inhibitors to treat IgG-mediated autoimmune diseases, with a pipeline of clinical trials anticipated to produce key data through 2025-2027, aiming for future regulatory approval and commercialization.

Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases, particularly through its lead candidates IMVT-1402 and batoclimab.

# Company Overview: Immunovant, Inc.

## Business Focus
Immunovant, Inc. is a clinical-stage immunology company specializing in the development of treatments for autoimmune diseases. The company is pursuing an anti-FcRn strategy utilizing its lead product candidate, **IMVT-1402**, and another candidate, **batoclimab**, which are fully human monoclonal antibodies designed to inhibit the neonatal fragment crystallizable receptor (FcRn). This inhibition is intended to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which are implicated in various autoimmune conditions.

## Product Pipeline
Immunovant has a robust product pipeline with significant focus on multiple autoimmune indications. The company plans to initiate development programs for **IMVT-1402** in therapeutic areas such as:

- **Endocrinology** (e.g., Graves’ disease)
- **Neurology** (e.g., Myasthenia gravis and Chronic Inflammatory Demyelinating Polyneuropathy)
  
Currently, the company is working on ten targeted indications and expects to have initiated clinical trials in all of them by March 31, 2026.

## Development Progress
- **IMVT-1402** is undergoing Phase 1 clinical trials, with reports showing promising reductions in IgG levels and a favorable safety profile.
- **Batoclimab** has completed pivotal studies and is also being used to inform the development of IMVT-1402.

## Key Metrics
- **Employees:** As of March 31, 2024, Immunovant had **207 full-time employees**, with a significant proportion involved in research and development.
- **Employee Demographics:** Approximately **59%** of employees have advanced degrees (Ph.D., M.D., M.B.A.), and over **50%** of the workforce is comprised of women. 
- **Revenue and Income:** The company has **not yet generated product revenue**. As of March 31, 2024, Immunovant reported a **net loss of $259.3 million** for the fiscal year and an **accumulated deficit of $825.7 million**.

## Market Strategy
Immunovant intends to build a targeted marketing and sales infrastructure in the U.S. to reach specialist physicians treating significant numbers of patients with autoimmune diseases. The company also plans to form strategic collaborations to maximize the commercial potential of its product candidates.

## Customer Base
While direct customer metrics such as the number of customers are not detailed, the company's potential customer base consists mainly of physicians who treat the target autoimmune conditions and the patients they serve.

## Conclusion
Immunovant, Inc. is positioned to become a key player in the autoimmune disease therapeutics market with its innovative pipeline featuring IMVT-1402 and batoclimab. However, it faces challenges typical of clinical-stage biopharmaceutical companies, including the need for successful clinical outcomes, regulatory approvals, and commercialization strategies to achieve its financial goals.

Immunovant, Inc.

10-K / May 29, 2025

10-K / May 29, 2024

10-K / May 29, 2025

Immunovant, Inc. Company Summary

Overview

Regulatory and Development Status

Business Focus & Strategy

Intellectual Property

Financial Information

Employees

Business Model & Commercialization

Collaborations & Agreements

Summary